Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Non Operating Investment Income: 2011-2014

Historic Non Operating Investment Income for Arrowhead Pharmaceuticals (ARWR) over the last 3 years, with Mar 2014 value amounting to $62,954.

  • Arrowhead Pharmaceuticals' Non Operating Investment Income changed negligibly% to $62,954 in Q1 2014 from the same period last year, while for Mar 2014 it was $251,816, marking a year-over-year negligible change of negligibly%. This contributed to the annual value of -$58,091 for FY2012, which is 77.76% up from last year.
  • Per Arrowhead Pharmaceuticals' latest filing, its Non Operating Investment Income stood at $62,954 for Q1 2014, which was down 0.00% from $62,954 recorded in Q4 2013.
  • Over the past 5 years, Arrowhead Pharmaceuticals' Non Operating Investment Income peaked at $62,954 during Q1 2012, and registered a low of -$498,406 during Q2 2011.
  • Moreover, its 3-year median value for Non Operating Investment Income was $62,954 (2014), whereas its average is $62,954.
  • Data for Arrowhead Pharmaceuticals' Non Operating Investment Income shows a peak YoY surged of 208.37% (in 2012) over the last 5 years.
  • Over the past 4 years, Arrowhead Pharmaceuticals' Non Operating Investment Income (Quarterly) stood at -$58,091 in 2011, then spiked by 208.37% to $62,954 in 2012, then remained steady at $62,954 in 2013, then remained steady at $62,954 in 2014.
  • Its last three reported values are $62,954 in Q1 2014, $62,954 for Q4 2013, and $62,954 during Q3 2013.